Can I read Pfizer Licenses SSGJ-707 from 3SBio on EtoBox?

Pfizer Licenses SSGJ-707 from 3SBio by misglasstrendz is a document available to read on EtoBox.

What is Pfizer Licenses SSGJ-707 from 3SBio about?

Pfizer has entered into an exclusive global licensing agreement with 3SBio for the development and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, which is currently in clinical trials for various cancers. 3SBio will receive an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion, along with royalties on sales if approved. The agreement is expected to close in the third quarter of 2025, pending regulatory and shareholder approvals.

Author

misglasstrendz

Language

EN